Novartis AG
NOVN.SWSMI
126,60 CHF
Dividend yield2,92 %
Continuity31 yr
Dividend3,70 CHF
DiviScore
ExcellentPerformance24/35
Dividend Quality32/35
AGM Date
—Ex-Date
10.03.2026Payment
—CAGR 3Y
+11.6%CAGR 5Y
+8.6%CAGR 10Y
+6.0%€10,000 invested in 2016 · with dividend reinvestment
End Value
24.950,41 CHF
Total Return
+149.5%
Annual Return
9.6% p.a.
Dividends Received
4.633,64 CHF
Dividend history
About Novartis AG
Novartis, based in Basel, is one of the world's largest pharmaceutical companies, focused on innovative prescription medicines in areas such as cancer, cardiovascular and immunology after spinning off its generics arm Sandoz. A deep pipeline and strong patent-protected drugs give it dependable, high-margin cash flow. Novartis has raised its dividend every year for three decades, a rare record backed by resilient healthcare profits, and adds large buybacks. A dependable, steadily growing payout from a defensive pharma giant gives it one of the highest DiviScores in the index.
Frequently Asked Questions
The next payment date is not yet announced.
Novartis AG has a DiviScore of 80/100. DiviScore rates dividend stocks based on price performance, dividend quality, fundamentals, and stability.
Novartis AG's current dividend yield is 2.92% based on the latest dividend.
Novartis AG (NOVN.SW) is a member of SMI. Current data including price, dividend, and DiviScore is updated daily.
DiviScore is a proprietary 100-point rating based on four pillars: Performance (35 pts), Dividend Quality (35 pts), Fundamentals (15 pts), and Stability (15 pts). It simulates a 10-year investment with automatic dividend reinvestment.